```html

Fibrolamellar Hepatocellular Carcinoma (FL‑HCC)

Overview

Fibrolamellar Hepatocellular Carcinoma (FL‑HCC) is a rare, distinct subtype of liver cancer that arises from liver cells (hepatocytes) but differs from the more common conventional hepatocellular carcinoma (HCC) in its biology, genetics, and patient profile.

• Who it affects: Unlike typical HCC, which is strongly linked to chronic liver disease, FL‑HCC most often occurs in adolescents and young adults (median age ≈ 25 years) and can affect individuals with otherwise healthy livers.
• Prevalence: FL‑HCC accounts for ~1–2 % of all primary liver cancers. In the United States, an estimated 150–200 new cases are diagnosed each year (American Cancer Society).
• Prognosis: Because it tends to present at an earlier stage and often without cirrhosis, surgical resection can be curative in 40–60 % of patients, giving a 5‑year survival of 40–70 % (better than conventional HCC) (J Hepatol, 2020).

Symptoms

Symptoms are frequently vague and may mimic benign liver conditions, which is why many patients are diagnosed after imaging for unrelated reasons. Below is a comprehensive list with brief explanations.

Common early symptoms

• Abdominal discomfort or pain – Usually a dull ache in the right upper quadrant (RUQ) where the liver sits.
• Unexplained weight loss – Loss of appetite or feeling full quickly (early satiety).
• Fatigue – Persistent tiredness not relieved by rest.
• Fever – Low‑grade fevers may occur, especially if the tumor is necrotic.

Symptoms that suggest tumor growth or spread

• Palpable abdominal mass – A firm lump can be felt under the rib cage.
• Jaundice – Yellowing of the skin and eyes, indicating bile duct obstruction or liver dysfunction.
• Ascites – Accumulation of fluid in the abdomen, causing swelling.
• Upper gastrointestinal bleeding – Vomiting blood or black stools (melena) if portal hypertension develops.
• Leg swelling (edema) – May accompany advanced liver disease.
• Chest pain or shortness of breath – Possible when lung metastases occur.

Rare but noteworthy signs

• Gynecomastia in males – Hormonal changes due to liver dysfunction.
• Itching (pruritus) – Bile salt buildup.
• Neurologic changes – Confusion or altered mental status if severe liver failure develops.

Causes and Risk Factors

The exact cause of FL‑HCC remains unknown, but several clues have emerged from research.

Genetic hallmark

• DNAJB1‑PRKACA fusion gene – Present in > 80 % of FL‑HCC tumors. This unique chromosomal rearrangement creates a chimeric protein that drives uncontrolled cell growth (Nature Genetics, 2014).

Known risk factors

• Age – Peak incidence between 10 and 35 years.
• Sex – Slight male predominance (≈ 60 % male).
• Ethnicity – No strong ethnic predilection; cases reported worldwide.
• Underlying liver disease – Unlike conventional HCC, most patients have **no** cirrhosis, hepatitis B/C, or alcohol‑related liver damage.
• Family history – Rare familial clusters suggest a possible inherited susceptibility, though no definitive germline mutation has been identified.

What does NOT increase risk

• Chronic hepatitis B or C infection.
• Heavy alcohol consumption.
• Non‑alcoholic fatty liver disease (NAFLD) – common in regular HCC but not a major factor for FL‑HCC.

Diagnosis

Because the disease is rare and its symptoms overlap with many benign conditions, a step‑wise diagnostic approach is essential.

1. Initial evaluation

• Medical history & physical exam – Focus on RUQ tenderness, palpable mass, and signs of liver dysfunction.
• Laboratory tests
  • Complete blood count (CBC) – May show anemia or thrombocytopenia.
  • Liver panel (AST, ALT, ALP, bilirubin) – Often normal or mildly elevated.
  • Alpha‑fetoprotein (AFP) – Usually < 20 ng/mL in FL‑HCC (helps distinguish from conventional HCC where AFP is often high).
  • Serum calcium & vitamin D – Occasionally elevated in FL‑HCC.

2. Imaging studies

• Ultrasound (US) – First‑line, detects a solid liver lesion; may show a heterogeneous mass with a central scar.
• Multiphasic contrast‑enhanced CT scan – Classic pattern: arterial‑phase hyperenhancement with rapid washout in portal venous phase, plus a central fibrous scar that enhances late.
• Magnetic Resonance Imaging (MRI) with hepatocyte‑specific contrast (gadoxetate) – Improves lesion characterization and identifies vascular involvement.
• Positron emission tomography (PET‑CT) – Useful for detecting extra‑hepatic metastases, especially to lungs and lymph nodes.

3. Tissue diagnosis

When imaging is suggestive but not definitive, a biopsy is performed.

• Core needle biopsy – Obtains sufficient tissue for histology and molecular testing.
• Pathology hallmarks
  • Large polygonal cells with abundant eosinophilic cytoplasm.
  • Prominent lamellar fibrosis (hence “fibrolamellar”).
  • Immunohistochemistry: Positive for HepPar‑1, Arginase‑1, and CK7; negative for typical HCC markers like Glypican‑3.
  • Detection of DNAJB1‑PRKACA fusion by RT‑PCR or next‑generation sequencing confirms the diagnosis.

4. Staging

Staging follows the AJCC (American Joint Committee on Cancer) 8th edition for liver cancer, incorporating tumor size, vascular invasion, nodal involvement, and distant metastasis.

Treatment Options

Treatment is individualized based on tumor stage, liver function, patient age, and overall health.

Surgical options – primary curative intent

• Partial hepatectomy (liver‑sparing resection) – Preferred when the tumor is confined to one lobe and adequate liver reserve remains. Five‑year survival after complete resection ranges from 40‑70 %.
• Liver transplantation – Considered for unresectable disease confined to the liver without extra‑hepatic spread, especially in younger patients. Limited data but reports of 5‑year survival > 60 % in selected cases.

Locoregional therapies (for unresectable or bridging to surgery)

• Radiofrequency ablation (RFA) or microwave ablation – Destroys small tumors (< 3 cm).
• Trans‑arterial chemoembolization (TACE) – Delivers chemotherapy directly into the tumor’s arterial supply; provides disease control but rarely curative.
• Selective internal radiation therapy (SIRT/Y‑90) – Radio‑embolization for larger or multifocal lesions.

Systemic therapies

• Chemotherapy regimens – Historically, a combination of cisplatin, doxorubicin, and 5‑fluorouracil (5‑FU) (the “CDFS” protocol) has shown modest response rates (~ 15‑30 %).
• Targeted agents – Trials with multikinase inhibitors (sorafenib, lenvatinib) have limited efficacy in FL‑HCC because of its distinct biology.
• Immunotherapy – Early‑phase studies of PD‑1 inhibitors (pembrolizumab, nivolumab) are ongoing; some case reports demonstrate partial responses.
• Experimental fusion‑specific therapy – Small‑molecule inhibitors aimed at the DNAJB1‑PRKACA fusion protein are in pre‑clinical development (as of 2024).

Supportive & lifestyle measures

• Maintain a balanced diet rich in lean protein, fruits, and vegetables.
• Stay physically active within tolerance (e.g., walking, gentle yoga).
• Avoid hepatotoxic substances: alcohol, unprescribed herbal supplements, and unnecessary acetaminophen.
• Vaccinate against hepatitis A and B if not immune (protects the remaining liver).

Living with Fibrolamellar Hepatocellular Carcinoma

Being diagnosed with a rare cancer can feel overwhelming. Below are practical tips for day‑to‑day management.

Medical follow‑up

• Schedule imaging (CT or MRI) every 3‑6 months after treatment to monitor for recurrence.
• Regular blood work to track liver function and calcium levels.
• Maintain a survivorship care plan with your oncologist, hepatologist, and primary care physician.

Nutrition

• Aim for 1.2–1.5 g protein/kg/day if you’re recovering from surgery.
• Consider a registered dietitian experienced in oncology for personalized meal planning.
• Limit high‑salt foods if you develop ascites.

Managing side effects

• Fatigue – Prioritize sleep, take short rest periods, and engage in light activity to boost energy.
• Nausea from chemo – Small frequent meals, ginger tea, and anti‑emetic medications prescribed by your team.
• Pain – Follow a stepwise analgesic plan; use acetaminophen first, then low‑dose opioids if needed under supervision.

Emotional health

• Join support groups (e.g., Liver Cancer Association, rare‑cancer forums).
• Consider counseling or cognitive‑behavioral therapy to address anxiety or depression.
• Mind‑body techniques such as meditation, breathing exercises, or tai chi can improve coping.

Practical considerations

• Keep a concise “Cancer Care Summary” (diagnosis, treatments, allergies) to share with new healthcare providers.
• Plan for possible time off work; discuss flexible schedules or remote options with your employer.
• Explore financial aid resources (e.g., patient assistance programs, nonprofit foundations) if treatment costs become burdensome.

Prevention

Because the exact cause of FL‑HCC is unknown and most cases arise in livers without prior disease, primary prevention is limited. However, general liver‑health measures may reduce the overall burden of liver disease and improve outcomes if FL‑HCC does develop.

• Avoid chronic alcohol abuse – Even though not a direct risk, protecting liver reserve is prudent.
• Vaccinate against hepatitis A and B – Prevents future liver injury.
• Maintain a healthy weight – Reduces risk of NAFLD, which could otherwise complicate management.
• Limit exposure to known hepatotoxins – Certain industrial chemicals (e.g., vinyl chloride) are linked to other liver cancers; use protective equipment if occupational exposure is possible.
• Family counseling – If a DNAJB1‑PRKACA fusion is identified in a family member, discuss genetic counseling with a specialist.

Complications

If left untreated or if the disease progresses, several serious complications can arise.

• Liver failure – Loss of functional liver tissue leads to jaundice, coagulopathy, and hepatic encephalopathy.
• Portal hypertension – Causes ascites, variceal bleeding, and splenomegaly.
• Metastatic spread – Common sites: lungs, peritoneum, and regional lymph nodes; can cause respiratory symptoms or abdominal pain.
• Hypercalcemia – Paraneoplastic secretion of PTH‑related peptide leading to weakness, confusion, and cardiac arrhythmias.
• Infection – Impaired immunity and liver dysfunction increase susceptibility to bacterial peritonitis or sepsis.

When to Seek Emergency Care

References

• American Cancer Society. cancer.org. Accessed June 2026.
• Mayo Clinic. Fibrolamellar Hepatocellular Carcinoma. mayoclinic.org. Updated 2024.
• J Hepatol. “Fibrolamellar carcinoma: review of the literature and current management.” 2020; 73(5):1025‑1035. PMC7021475.
• Nature Genetics. “Recurrent DNAJB1‑PRKACA fusion in fibrolamellar hepatocellular carcinoma.” 2014. PMC6262268.
• National Institutes of Health (NIH). ClinicalTrials.gov – Ongoing studies for FL‑HCC. clinicaltrials.gov.
• Cleveland Clinic. Liver Cancer Treatment Options. clevelandclinic.org. Accessed 2025.

```